艾曲波帕在血小板减少中的应用进展  

Application progress of eltrombopag in thrombocytopenia

作　　者：余洪艳 杨桂玲[1] 汤爱平[1] 警富明 Yu Hongyan;Yang Guiling;Tang Aiping;Zi Fuming(Department of Hematology, the Second Affiliated Hospital of Ncinchang University,Institute of Hematology, Nanchang University. Jiatigjri Key Laboratory of Hematology, Nanchang 330006, Jiangxi Province China;Yu Hongyan is workirig on Chongqing Red Cross Hospital, Chongqing 400000, China)

机构地区：[1]南昌大学第二附属医院血液科.南昌大学血液病研究所,江西省血液病重点实验室330006 [2]重庆市红十字会医院,重庆400000

出　　处：《国际输血及血液学杂志》2019年第1期46-52,共7页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金项目(81560030);江西省自然科学基金项目20151BAB205021);江西省科技厅社发项目(20151BBG70170).

摘　　要：血小板减少是临床中常见的疾病,严重者可危及生命。血小板生成素受体激动剂(TPO-RA)可有效提高血小板减少患者的血小板计数,减少输血依赖。目前,第2代TPO-RA艾曲波帕已被批准用于慢性免疫性血小板减少症(cITP)、重型再生障碍性贫血(SAA)及慢性丙型肝炎病毒(HCV)感染等疾病相关血小板减少。笔者拟就艾曲波帕在血小板减少中的应用进展进行综述。Thrombocytopenia is a common disease in the clinic. In severe cases, it can be life-threatening. Thrombopoietin receptor agonists (TPO-RA) can effectively increase platelet counts in patients with thrombocytopenia and reduce blood transfusion dependence. As the second-generation TPO-RA, eltrombopag (EP) has been approved for thrombocytopenia caused by chronic immune thrombocytopenic purpura (cITP), severe aplastic anemia(SAA), and infection of chronic hepatitis C (HCV). This article reviews the progress of the application of EP in thrombocytopenia.

关 键 词：受体.血小板生成素 血小板减少 肝炎 丙型 贫血 再生障碍性 艾曲波帕 

分 类 号：R558.2[医药卫生—血液循环系统疾病]